<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03102645</url>
  </required_header>
  <id_info>
    <org_study_id>TCA-UPR-0001</org_study_id>
    <nct_id>NCT03102645</nct_id>
  </id_info>
  <brief_title>Does Single Dose Imipramine Affect the Opening Pressure of the Urethral and Anal Sphincter?</brief_title>
  <official_title>Effect of Single Dose Imipramine on the Urethral and Anal Sphincter in Healthy Women Measured With Urethral Pressure Reflectometry (UPR) and Anal Acoustic Reflectometry (AAR)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jonatan Kornholt</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bispebjerg Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      A double-blinded, randomized, crossover study in healthy females with placebo and single dose&#xD;
      imipramine 50 mg.&#xD;
&#xD;
      Primary objective: Does imipramine increase the tone of the external urethral sphincter?&#xD;
      Urethral Opening Pressure (UOP) is measured with Urethral Pressure Reflectometry (UPR). UOP&#xD;
      increases correlate with effect in treating stress urinary incontinence. Can imipramine treat&#xD;
      stress urinary incontinence? Secondary objective: Does imipramine increase the tone of the&#xD;
      anal sphincter? The opening pressure is measured with Anal Acoustic Reflectometry (AAR). The&#xD;
      investigators also wish to establish the within-subject standard deviation for AAR to enable&#xD;
      power calculations in future studies.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">May 16, 2017</start_date>
  <completion_date type="Actual">June 21, 2017</completion_date>
  <primary_completion_date type="Actual">June 16, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>16 healthy female subjects. Double-blinded, crossover study on two days with 1 week washout. Either placebo or imipramine 50 mg single dose before and after measurement of UOP and AOP.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
    <masking_description>Packaging, randomization and masking of investigational drugs (imipramine and placebo) by Region Hovedstadens Apothecary before delivery to investigator. Sealed envelope with participant ID and drug data will be opened after data analysis.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>Urethral Opening Pressure (UOP)</measure>
    <time_frame>Immediately before drug/placebo administration (baseline) and 1 hour after drug/placebo administration on both study days.</time_frame>
    <description>Mean change in UOP (baseline and 1 hour after drug administration). Measured with Urethral Pressure Reflectometry (UPR).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Anal Opening Pressure (AOP)</measure>
    <time_frame>Immediately before drug/placebo administration (baseline) and 1 hour after drug/placebo administration on both study days.</time_frame>
    <description>Mean change in AOP (baseline and 1 hour after drug administration). Measured with Anal Acoustic Reflectometry (AAR).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Urinary Incontinence, Stress</condition>
  <condition>Fecal Incontinence</condition>
  <arm_group>
    <arm_group_label>Imipramine first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo first</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo Oral Tablet</intervention_name>
    <description>Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc</description>
    <arm_group_label>Imipramine first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Imipramine Hydrochloride 25 MG</intervention_name>
    <description>Two Imipramin DAK film coated tablets 25 mg each, single dose</description>
    <arm_group_label>Imipramine first</arm_group_label>
    <arm_group_label>Placebo first</arm_group_label>
    <other_name>Imipramin DAK</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed consent form.&#xD;
&#xD;
          -  Healthy.&#xD;
&#xD;
          -  Female.&#xD;
&#xD;
          -  Non-smoker.&#xD;
&#xD;
          -  Age 18 to 55, both inclusive.&#xD;
&#xD;
          -  Normal weight: BMI 19.5 to 30.0 kg/m2. Weight minimum 50 kg.&#xD;
&#xD;
          -  No breastfeeding.&#xD;
&#xD;
          -  No pregnancy during the study.&#xD;
&#xD;
          -  No other clinical trials during the study.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Known allergy to imipramine or any of the other known constituents.&#xD;
&#xD;
          -  Medical history with significant cardiovascular, gastrointestinal, endocrinologic,&#xD;
             hematologic, immunologic, metabolic, genitourologic, dermatologic, psychiatric,&#xD;
             neurologic or dermatologic disease, lung disease, kidney disease, malignant disease or&#xD;
             other significant diseases as assessed by the investigator.&#xD;
&#xD;
          -  Medical history of urinary incontinence.&#xD;
&#xD;
          -  Infectious disease 1 week prior to study day 1 or study day 2.&#xD;
&#xD;
          -  Clinically significant findings during the physical examination.&#xD;
&#xD;
          -  Pregnancy.&#xD;
&#xD;
          -  Heart rate &lt; 40 or &gt; 100 beats per minute. Mean systolic blood pressure &gt; 140 mmHg or&#xD;
             mean diastolic blood pressure &gt; 90 mmHg (mean of the measures on the screening day).&#xD;
&#xD;
          -  Prescription, over the counter or herbal medication two weeks prior to study day 1 or&#xD;
             study day 2. Excluding paracetamol and excluding oral contraceptives.&#xD;
&#xD;
          -  Smoking 3 months prior to study day 1 or study day 2.&#xD;
&#xD;
          -  Alcohol abuse, meaning &gt; 14 units (12 g alcohol) per week within three weeks prior to&#xD;
             study day 1 or study day 2.&#xD;
&#xD;
          -  Drug abuse 3 months prior to study day 1 or study day 2.&#xD;
&#xD;
          -  Any condition as assessed by the investigator.&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jonatan Kornholt, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinisk farmakologisk afdeling, Bispebjerg Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Zelo Phase I Unit, Dept. of Clinical Pharmacology, Bispebjerg Hospital</name>
      <address>
        <city>Copenhagen</city>
        <state>Copenhagen NV</state>
        <zip>2400</zip>
        <country>Denmark</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Denmark</country>
  </location_countries>
  <verification_date>January 2021</verification_date>
  <study_first_submitted>March 20, 2017</study_first_submitted>
  <study_first_submitted_qc>March 30, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">April 6, 2017</study_first_posted>
  <results_first_submitted>April 9, 2019</results_first_submitted>
  <results_first_submitted_qc>January 25, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">February 12, 2021</results_first_posted>
  <last_update_submitted>January 25, 2021</last_update_submitted>
  <last_update_submitted_qc>January 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 12, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Bispebjerg Hospital</investigator_affiliation>
    <investigator_full_name>Jonatan Kornholt</investigator_full_name>
    <investigator_title>Resident doctor in the Department of Clinical Pharmacology</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fecal Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence</mesh_term>
    <mesh_term>Urinary Incontinence, Stress</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Imipramine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>July 26, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/45/NCT03102645/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>Subjects were included from 16 May 2017 to 31 May 2017 and the study days was conducted from 17 May 2017 to 16 June 2017 and the last followup call to detect adverse effects was 21 June 2017.</recruitment_details>
      <pre_assignment_details>Randomization determining order of arms after enrollment. At least 1 week wash out between study days. Followup 5 days after last study day to collect adverse events.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Imipramine First</title>
          <description>A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2&#xD;
Placebo Oral Tablet: Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc&#xD;
Imipramine Hydrochloride 25 MG: Two Imipramin DAK film coated tablets 25 mg each, single dose</description>
        </group>
        <group group_id="P2">
          <title>Placebo First</title>
          <description>A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2&#xD;
Placebo Oral Tablet: Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc&#xD;
Imipramine Hydrochloride 25 MG: Two Imipramin DAK film coated tablets 25 mg each, single dose</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="8"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Imipramine First</title>
          <description>A: Imipramine Hydrochloride 25 MG x2 B: Placebo Oral Tablet x2&#xD;
Placebo Oral Tablet: Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc&#xD;
Imipramine Hydrochloride 25 MG: Two Imipramin DAK film coated tablets 25 mg each, single dose</description>
        </group>
        <group group_id="B2">
          <title>Placebo First</title>
          <description>A: Placebo Oral Tablet x2 B: Imipramine Hydrochloride 25 MG x2&#xD;
Placebo Oral Tablet: Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc&#xD;
Imipramine Hydrochloride 25 MG: Two Imipramin DAK film coated tablets 25 mg each, single dose</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="8"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race and Ethnicity Not Collected</title>
          <population>Race and Ethnicity were not collected from any participant.</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="0"/>
                    <count group_id="B2" value="0"/>
                    <count group_id="B3" value="0"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Denmark</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="B1" value="8"/>
                    <count group_id="B2" value="8"/>
                    <count group_id="B3" value="16"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="16"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Urethral Opening Pressure (UOP)</title>
        <description>Mean change in UOP (baseline and 1 hour after drug administration). Measured with Urethral Pressure Reflectometry (UPR).</description>
        <time_frame>Immediately before drug/placebo administration (baseline) and 1 hour after drug/placebo administration on both study days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imipramine</title>
            <description>Imipramine Hydrochloride 25 MG: Two Imipramin DAK film coated tablets 25 mg each, single dose.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc</description>
          </group>
        </group_list>
        <measure>
          <title>Urethral Opening Pressure (UOP)</title>
          <description>Mean change in UOP (baseline and 1 hour after drug administration). Measured with Urethral Pressure Reflectometry (UPR).</description>
          <units>cmH2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.90411" spread="13.24729"/>
                    <measurement group_id="O2" value="-3.623431" spread="8.279883"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CROS test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.07</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>CROS. DF=14.</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>6.5</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-0.5</ci_lower_limit>
            <ci_upper_limit>13.5</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Anal Opening Pressure (AOP)</title>
        <description>Mean change in AOP (baseline and 1 hour after drug administration). Measured with Anal Acoustic Reflectometry (AAR).</description>
        <time_frame>Immediately before drug/placebo administration (baseline) and 1 hour after drug/placebo administration on both study days.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Imipramine</title>
            <description>Imipramine Hydrochloride 25 MG: Two Imipramin DAK film coated tablets 25 mg each, single dose.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo Oral Tablet: Placebo film coated tablet: Lactose monohydrate, potato starch, gelatine, magnesium stearate, talc.</description>
          </group>
        </group_list>
        <measure>
          <title>Anal Opening Pressure (AOP)</title>
          <description>Mean change in AOP (baseline and 1 hour after drug administration). Measured with Anal Acoustic Reflectometry (AAR).</description>
          <units>cmH2O</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="16"/>
                <count group_id="O2" value="16"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.11873" spread="15.79818"/>
                    <measurement group_id="O2" value="-2.989054" spread="16.40355"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>CROS test</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.03</p_value>
            <method>t-test, 2 sided</method>
            <method_desc>CROS test</method_desc>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>2.0</ci_lower_limit>
            <ci_upper_limit>28.2</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>From study day 1 to 5 days after 2nd study day.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Imipramine</title>
          <description>Imipramine Hydrochloride 25 MG x2: Two Imipramin DAK film coated tablets 25 mg each, single dose</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo Oral Tablet x2: Two placebo film coated tablets containing lactose monohydrate, potato starch, gelatine, magnesium stearate, and talc</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="7" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Stomach cramps</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Dry mouth</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Tired</sub_title>
                <counts group_id="E1" events="5" subjects_affected="5" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizzy</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Migraine</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="16"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jonatan Kornholt</name_or_title>
      <organization>Department of Clinical Pharmacology, University Hospital Bispebjerg and Frederiksberg</organization>
      <phone>+4538635604</phone>
      <email>jonatan.kornholt@regionh.dk</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

